SUMMARY
The collaborative research of Ann L. Oberg, Ph.D., is motivated by her clinical collaborators at Mayo Clinic. She is an established collaborative statistician with broad research experience in cell lines, xenografts, and both retrospective and prospective human studies. Dr. Oberg's research has an emphasis on understanding disease mechanisms and markers of disease in ovarian cancer and pancreatic cancer. Much of her work makes use of large-scale genomic data of various types, such as mRNA expression, protein mass spectrometry and DNA methylation.
Dr. Oberg is the director of the Biostatistics Core for both the Mayo Clinic Ovarian Cancer SPORE and the Mayo Clinic Pancreatic Cancer SPORE. She is also the associate group statistician and the director of the Computational Genomics and Bioinformatics Unit, both for the Alliance for Clinical Trials in Oncology. Dr. Oberg is a member of Mayo Clinic Comprehensive Cancer Center and holds full faculty privileges at Mayo Clinic College of Medicine and Science.
Focus areas
- Developing prognostic models of cancer risk
- Normalization methods and experimental design for large-scale genomic data
- Experimental design and analysis strategies for patient-derived xenograft models
Significance to patient care
Dr. Oberg's collaborations and research are directed at finding markers of disease or response to treatment so that disease can be detected early enough for successful treatment and patients can receive optimal treatments. Her work also helps improve understanding of disease mechanisms so that treatments can be better tailored to patient characteristics.